A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 7, 2005, Pages 899-907

  De Wet, N T E ^a   Bester, A J ^b   Viljoen, J J ^c   Filho, F ^d   Suleiman, J M ^e   Ticona, E ^f   Llanos, E A ^g   Fisco, C ^h   Lau, W ^h   Buell, D ^h  

^a Prime Care Clinic   (South Africa)

^b Eastmed Medical Centre   (South Africa)

^c Genclin Corp   (South Africa)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^f HOSPITAL NACIONAL DOS DE MAYO   (Peru)

^g UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^h ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPY; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DISEASE; FEMALE; FEVER; HEADACHE; HUMAN; INCIDENCE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; FEMALE; FLUCONAZOLE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 20144387002     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02427.x     Document Type: Article

References (21)

1. Darouiche RO. Oropharyngeal and oesophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26: 259-72.
2. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124: 633-42.
3. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-91.
4. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of oesophageal candidiasis. J Infect Dis 1997; 176: 227-32.
5. Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 1999; 15: 1405-12.
6. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
7. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
8. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614-8.
9. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent. FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53: 1175-81.
10. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
11. Hatano K, Morishita Y, Nakai T, Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55: 219-22.
12. van Burik JH, Ratanatharathorn V, Stepan DE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
13. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of oesophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
14. Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. CA, 24-2 7 September, 1998 (Abstract F-146).
15. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
16. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475-81.
17. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
18. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
19. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of oesophageal candidiasis. Am J Med 2002; 113: 294-9.
20. DiNubile MJ, Lupinacci RJ, Berman RS, Sable CA. Response and relapse rates of candidal oesophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 2002; 18: 903-8.
21. Rex JH, Rinaldl MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.